
BioNTech reports high efficacy of COVID-19 vaccine
BioNTech/Pfizer are the first COVID-19 vaccine developers who provided the definitive proof-of-concept that it is possible to protect people from an...

1,800+ experts will join the Global Bioeconomy Summit
First editions of the summit took place in Berlin in 2015 and 2018, this year it will be delivery fully virtually. The digital conference event...

Omnix Medical bags €10.8m from EIC Accerator Fund
The money for the trial comes from the EIC Accelerator, for which last year 38 companies with potential breakthrough innovations were selected to...

COVID-19: Moderna reports promising interim results
On Monday, Moderna Inc. announced that two 100µg shots of its mRNA COVID-19 vaccine candidate mRNA-1273 showed an efficacy of 94,5%, according to an...

Centogene and Anylam launch clinical programme
ATTRv is an autosomal dominant condition caused by a pathogenic variant in the TTR gene coding for transthyretin (prealbumin)....

3,000+ experts discuss bioeconomy globally
First editions of the summit took place in Berlin in 2015 and 2018. This year, due to the pandemic, it is not taking place in Berlin as...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...